Eli Lilly and Company

NYSE:LLY Stock Report

Market Cap: US$691.3b

Eli Lilly Past Earnings Performance

Past criteria checks 4/6

Eli Lilly has been growing earnings at an average annual rate of 5.7%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 11.2% per year. Eli Lilly's return on equity is 58.4%, and it has net margins of 20.5%.

Key information

5.7%

Earnings growth rate

6.3%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate11.2%
Return on equity58.4%
Net Margin20.5%
Next Earnings Update06 Feb 2025

Recent past performance updates

Recent updates

Eli Lilly: A Rare Buying Opportunity

Dec 17

Eli Lilly (NYSE:LLY) Has Announced That It Will Be Increasing Its Dividend To $1.50

Dec 14
Eli Lilly (NYSE:LLY) Has Announced That It Will Be Increasing Its Dividend To $1.50

Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy

Dec 04

Here's Why Eli Lilly (NYSE:LLY) Can Manage Its Debt Responsibly

Nov 29
Here's Why Eli Lilly (NYSE:LLY) Can Manage Its Debt Responsibly

Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)

Nov 28

Eli Lilly Stock: Unexpected Developments (Rating Downgrade)

Nov 21

Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next

Nov 01
Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next

Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges

Oct 30

Eli Lilly Buy On Weakness Signal (Technical Analysis)

Oct 20

Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis

Sep 30

Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects  (Upgrade)

Sep 20

Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth

Sep 18
Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth

Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside

Sep 04

Eli Lilly: Tirzepatide's Winning Streak Continues

Aug 20

Revenue & Expenses Breakdown

How Eli Lilly makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:LLY Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2440,8638,3707,63310,531
30 Jun 2438,9237,3427,33710,206
31 Mar 2435,9326,1387,1449,851
31 Dec 2334,1245,2406,9419,313
30 Sep 2332,0734,9886,6828,747
30 Jun 2329,5166,4986,5158,140
31 Mar 2327,6915,6876,2367,566
31 Dec 2228,5416,2456,0687,191
30 Sep 2229,2406,0336,0377,093
30 Jun 2229,0715,6926,0206,996
31 Mar 2229,3236,1296,1046,869
31 Dec 2128,3185,5826,1426,931
30 Sep 2127,7595,9726,1196,870
30 Jun 2126,7266,0716,0696,631
31 Mar 2125,4866,0935,8676,366
31 Dec 2024,5406,1945,8695,976
30 Sep 2023,2145,5736,0195,829
30 Jun 2022,9505,6185,9245,745
31 Mar 2023,0875,5336,0485,757
31 Dec 1922,3204,6386,0045,595
30 Sep 1921,8434,2645,9845,405
30 Jun 1921,6734,1036,0195,305
31 Mar 1921,6222,5455,9135,174
31 Dec 1821,4933,1515,7355,051
30 Sep 1822,0163725,8555,146
30 Jun 1822,368-1665,9755,205
31 Mar 1822,6071,0746,2105,207
31 Dec 1719,974-865,7335,096
30 Sep 1722,4712,2256,4755,321
30 Jun 1722,0052,4476,5265,217
31 Mar 1721,5852,1876,4835,281
31 Dec 1621,2222,7386,3305,310
30 Sep 1620,8372,4446,4605,238
30 Jun 1620,6052,4666,4715,145
31 Mar 1620,1792,3196,4834,978
31 Dec 1519,9592,4086,5334,796
30 Sep 1519,7042,3596,5354,538
30 Jun 1519,6202,0596,6314,638
31 Mar 1519,5772,1926,6594,664
31 Dec 1419,6162,3916,6214,734
30 Sep 1420,3032,6906,7755,023
30 Jun 1421,2003,3926,7555,158
31 Mar 1422,1943,8656,9595,293
31 Dec 1323,1134,6857,1265,531

Quality Earnings: LLY has a high level of non-cash earnings.

Growing Profit Margin: LLY's current net profit margins (20.5%) are higher than last year (15.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: LLY's earnings have grown by 5.7% per year over the past 5 years.

Accelerating Growth: LLY's earnings growth over the past year (67.8%) exceeds its 5-year average (5.7% per year).

Earnings vs Industry: LLY earnings growth over the past year (67.8%) exceeded the Pharmaceuticals industry 54.6%.

Return on Equity

High ROE: Whilst LLY's Return on Equity (58.45%) is outstanding, this metric is skewed due to their high level of debt.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:15
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eli Lilly and Company is covered by 63 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Ishan MajumdarBaptista Research
Alistair CampbellBerenberg